Grazoprevir/elbasvir regulatory update

Merck submitted an NDA to FDA for grazoprevir/elbasvir to treat chronic HCV genotype 1, 4 and 6 infection in adults. The once-daily, fixed-dose oral combination of grazoprevir, an HCV NS3/4A protease ...